Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jerry W Mitchell"'
Autor:
John M. Kirkwood, Robert M. Conry, Phu V. Truong, Noel Laudi, Mark A. Taylor, Stuart J. Wong, Jerry W. Mitchell, Mark R. Albertini, Arun Nagarajan, Uma N.M. Rao, Xiaoxue Li, Sandra J. Lee, Ahmad A. Tarhini
Table S1- Tumor response by RECIST criteria. Table S2- Treatment details and reasons for discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a6907f54d47ccf983238e8a3eb7ab9
https://doi.org/10.1158/1078-0432.22472835
https://doi.org/10.1158/1078-0432.22472835
Autor:
John M. Kirkwood, Robert M. Conry, Phu V. Truong, Noel Laudi, Mark A. Taylor, Stuart J. Wong, Jerry W. Mitchell, Mark R. Albertini, Arun Nagarajan, Uma N.M. Rao, Xiaoxue Li, Sandra J. Lee, Ahmad A. Tarhini
Purpose:Interferon-α favors a Th1 shift in immunity, and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive effects, leading to more durable antitumor immune responses. A study of tremelimumab and high-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8f49c27d3cb02f045ae490cbef5e57
https://doi.org/10.1158/1078-0432.c.6528342.v1
https://doi.org/10.1158/1078-0432.c.6528342.v1
Autor:
Elizabeth A. Salerno, Eva Culakova, Charles E. Matthews, Charles E. Heckler, Michelle C. Janelsins, Amber S. Kleckner, Alison Conlin, Po-Ju Lin, Jerry W. Mitchell, Karen M. Mustian, Lora Weiselberg
Publikováno v:
J Clin Oncol
PURPOSE Physical activity (PA) is a promising intervention for cancer-related cognitive decline, yet research assessing its use during chemotherapy is limited. This study evaluated patterns of PA before, during, and after chemotherapy in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::720588ac56344c43af1eadbb68fec199
https://europepmc.org/articles/PMC8500586/
https://europepmc.org/articles/PMC8500586/
Autor:
Mark A. Taylor, John M. Kirkwood, Jerry W Mitchell, Phu Van Truong, Ahmad A. Tarhini, Robert M. Conry, Mark R. Albertini, Xiaoxue Li, Noel Laudi, Arun Nagarajan, Uma N. M. Rao, Sandra J. Lee, Stuart J. Wong
Publikováno v:
Clinical Cancer Research. 25:524-532
Purpose: Interferon-α favors a Th1 shift in immunity, and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive effects, leading to more durable antitumor immune responses. A study of tremelimumab and high-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::481900f87e00cc80d47ed818420784a4
https://doi.org/10.1158/1078-0432.ccr-18-2258
https://doi.org/10.1158/1078-0432.ccr-18-2258
Autor:
Ann M. O'Mara, Victor Kipnis, Jerry W. Mitchell, Amber S. Kleckner, Charles S. Kamen, Luke J. Peppone, AnnaLynn M Williams, Jodi Geer, Carly Paterson Khan, Karen Mustian, Shaker R. Dakhil, Michelle C Janelsins, C. E. Heckler, Mary Ontko, Debra L. Barton
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Fatigue and anxiety are common and significant symptoms reported by cancer patients. Few studies have examined the trajectory of multidimensional fatigue and anxiety, the relationships between them and with quality of life. METHODS: Breast c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71bc9e6aa63c81a412fdbb765c252c79
https://europepmc.org/articles/PMC8080260/
https://europepmc.org/articles/PMC8080260/
Autor:
Charles E. Heckler, Luke J. Peppone, Lora Weiselberg, Charles Kamen, Supriya G. Mohile, Tim A. Ahles, Jerry W. Mitchell, Joseph J. Guido, Gary R. Morrow, Karen M. Mustian, Alison Conlin, Christine A. Ambrosone, Kelley Lynn Young, Michelle C. Janelsins, Allison Magnuson, Ian R. Kleckner
Publikováno v:
Journal of Clinical Oncology. 35:506-514
Purpose Cancer-related cognitive impairment is an important problem for patients with breast cancer, yet its trajectory is not fully understood. Some previous cancer-related cognitive impairment research is limited by heterogeneous populations, small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e07606db9d4d54cb93dd3438f7ccb941
https://doi.org/10.1200/jco.2016.68.5826
https://doi.org/10.1200/jco.2016.68.5826
Autor:
Jerry W. Mitchell, Huiwen Xu, Amber S. Kleckner, Nikesha Gilmore, Michelle C. Janelsins, Po-Ju Lin, Supriya G. Mohile, Lianlian Lei, Lora Weiselberg, Elizabeth Belcher, Kah Poh Loh, Mary Ontko
Publikováno v:
Journal of Clinical Oncology. 38:549-549
549 Background: Chemotherapy adversely affects physical function. While many patients recover after treatment (i.e. are resilient), some are unable to return to their pre-treatment function (i.e. are non-resilient). Since immune dysfunction may play
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c1898d086f3f5577306fba708c1f435
https://doi.org/10.1200/jco.2020.38.15_suppl.549
https://doi.org/10.1200/jco.2020.38.15_suppl.549
T. R. M. Howard: Doctor, Entrepreneur, Civil Rights Pioneer tells the remarkable story of one of the early leaders of the Civil Rights Movement. A renaissance man, T. R. M. Howard (1908-1976) was a respected surgeon, important black community leader,
Autor:
Michael Goodman, Glenn J. Lesser, Jaclyn J. Renfrow, Jerry W. Mitchell, Leigh A. Mellen, John A. Wilson, Ryan T. Mott
Publikováno v:
Oncology Letters
Plasma cell granuloma is a pathological entity reported in nearly every organ system; however, intracranial cases remain rare. In the current case report, we present a case of intracranial plasma cell granuloma with the longest known follow-up period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb8f8b833820d0e585dea9ee40443c9
http://europepmc.org/articles/PMC3881914
http://europepmc.org/articles/PMC3881914
Autor:
Sandra J. Lee, Mark A. Taylor, Robert M. Conry, Mark R. Albertini, Phu Van Truong, Stuart J. Wong, John M. Kirkwood, Uma N. M. Rao, Jerry W. Mitchell, Ahmad A. Tarhini, Noel Laudi, Arun Nagarajan
Publikováno v:
Journal of Clinical Oncology. 35:9542-9542
9542 Background: Interferon-α (IFN) favors a Th1 shift in immunity. Combining CTLA4 blockade with IFN may downregulate CTLA4 suppressive elements. Prior data from a phase II of tremelimumab and HDI showed promising efficacy supporting the current st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd10b9e99feb3a6d42706aafe8d930a4
https://doi.org/10.1200/jco.2017.35.15_suppl.9542
https://doi.org/10.1200/jco.2017.35.15_suppl.9542